GleamWall
中文EN

NPCE NeuroPace Inc

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1528287 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.9%
TTM net income YoY21.1%
TTM EPS YoY25.3%
Revenue 3-yr CAGR16.3%
Net income 3-yr CAGR—

Margins

Gross margin81.4%
Operating margin-15.4%
Net margin-20.0%
FCF margin-13.1%
EBITDA margin-15.0%

Returns

ROE-126.1%
ROA-18.7%
ROIC (approx.)-19.7%
Asset turnover0.94x

Leverage & solvency

Liabilities / assets87.9%
Debt / equity5.15x
Current ratio5.26x
Interest coverage-2.34x

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$23.10M$22.83M$22.07M$26.59M$23.35M$19.50M$22.52M$21.47M
Cost of revenue$3.63M$3.92M$4.02M$6.01M$4.18M$3.29M$5.18M$5.28M
Gross profit$19.47M$18.91M$18.05M$20.58M$19.17M$16.21M$17.34M$16.19M
R&D expense$6.17M$6.90M$7.19M$7.03M$6.58M$6.84M$7.44M$6.05M
SG&A expense$4.22M$5.03M$4.84M$4.38M$4.59M$6.07M$4.05M$3.84M
Operating income-$2.08M-$5.14M-$5.57M-$1.77M-$4.03M-$8.19M-$5.15M-$3.65M
Interest expense$1.56M$1.54M$1.52M$1.60M$1.65M$2.06M$2.15M$2.19M
Income tax——$0$0$0$0$0—
Net income-$3.30M-$6.20M-$6.69M-$2.73M-$3.50M-$8.65M-$6.59M-$5.25M
EBITDA-$1.98M-$5.04M-$5.51M-$1.69M-$3.92M-$8.09M-$5.10M-$3.60M
EPS (basic)-0.10-0.18-0.20—-0.11-0.26-0.21—
EPS (diluted)-0.10-0.18-0.20—-0.11-0.26-0.21—
Dividends declared per share0.000.000.000.000.000.000.00—
Weighted avg. shares (diluted)34.35M34.10M33.72M—33.13M32.86M31.48M—
Balance sheet
Cash & equivalents$10.23M$12.54M$14.78M$21.69M$20.65M$22.86M$27.02M$13.55M
Short-term investments$39.00M$39.16M$39.20M$39.37M$39.37M$39.28M$39.24M$39.33M
Receivables$14.28M$14.93M$14.79M$12.94M$14.94M$13.55M$15.44M$12.85M
Inventory$18.80M$18.11M$16.69M$14.86M$18.14M$16.35M$13.58M$13.38M
Current assets$84.54M$86.19M$86.98M$94.07M$95.33M$93.74M$97.48M$81.34M
PP&E, net$1.16M$1.24M$1.28M$1.12M$1.11M$1.16M$1.16M$1.05M
Total assets$94.78M$96.99M$98.90M$105.56M$107.25M$106.11M$110.20M$94.65M
Current liabilities$16.07M$17.43M$16.17M$17.81M$19.61M$17.14M$14.71M$15.16M
Long-term debt$59.16M$59.01M$59.02M$58.88M$58.75M$58.62M$59.79M$59.52M
Total debt$59.16M$59.01M$59.02M$58.88M$58.75M$58.62M$59.79M$59.52M
Total liabilities$83.28M$85.11M$84.44M$86.53M$88.74M$86.68M$85.94M$86.63M
Shareholders' equity$11.49M$11.88M$14.45M$19.03M$18.52M$19.44M$24.27M$8.01M
Net debt$48.92M$46.48M$44.24M$37.19M$38.10M$35.76M$32.77M$45.97M
Shares outstanding34.43M34.28M33.91M33.57M33.28M33.04M32.75M30.15M
Cash flow statement
Operating cash flow-$2.76M-$3.90M-$5.90M$506,000-$1.94M-$2.09M-$7.48M-$4.80M
Capital expenditure$16,000$125,000$117,000$97,000$30,000$168,000$37,000$39,000
Free cash flow-$2.78M-$4.03M-$6.02M$409,000-$1.97M-$2.25M-$7.52M-$4.84M
Investing cash flow-$16,000-$125,000-$117,000-$97,000-$30,000-$168,000-$37,000$1.96M
Financing cash flow$477,000$1.18M-$166,000$635,000-$235,000-$1.91M$21.11M$848,000
Depreciation & amortization$100,000$100,000$60,000$80,000$100,000$100,000$49,000$48,000
Stock-based compensation$2.43M$2.30M$2.28M$2.61M$2.63M$3.23M$2.63M$2.60M
Share buybacks$0$0$0$0$0$0$49.55M$0

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.